

Nd:YAG Laser Capsulotomy for Treating Posterior Capsule Opacification

Gregor Hawlina, Brigita Drnovšek-Olup

Eye Hospital, University Medical Centre Ljubljana, Grablovičeva 46, 1525 Ljubljana, Slovenia

SUMMARY

Posterior capsule opacification (PCO) is the most common visually disabling consequence of modern cataract surgery and has important medical, social and economic implications¹.

The reported incidence of PCO varies widely. Analysis of multiple reports has found the visually significant PCO rate overall to be approximately 28% at 5 years².

At present, the most effective treatment of PCO is Nd:YAG laser capsulotomy. The procedure involves clearing of the visual axis by creating a central opening in the opacified posterior capsule^{3,4} by focusing a Nd:YAG laser pulse, with energy of few millijoules and duration of a few nanoseconds, just behind the posterior capsule.

Adverse effects following Nd:YAG laser capsulotomy reported in literature include intraocular pressure elevation and glaucoma, cystoid macular oedema, endothelial cells reduction and damage, retinal tears and detachment⁵⁻⁷ and, most commonly, intraocular lens (IOL) damage, or so-called pitting⁸. Some authors reported that side effects were more pronounced when higher single-pulse energy rather than higher total energy was used⁹⁻¹⁴. Numerous studies have analyzed the damage rate and damage thresholds of different lens material^{8, 15-24}. All have proposed that the procedure should be performed at the lowest possible energy level in order to avoid IOL damage.

The purpose of this study was to observe the total energy delivered while performing the Nd:YAG laser capsulotomy using a cruciate pattern with a size of 4 mm and single-pulse energy of 1.6 mJ.

All procedures were performed by the same ophthalmologist (G.H.) with an Nd:YAG laser (OptoYAG, Optotek d.o.o., Slovenia), emitting laser light at 1064 nm with a pulse duration of 4 ns.

Nd:YAG capsulotomies were performed taking into account the survey of UK practices and

recommendations published by Gomaa and Liu²⁵. The pupils were dilated and the capsulotomy aimed at a size of 4.0 mm. The procedure was started by setting the laser power slightly above damage threshold (1.6 mJ) with a backfocus of 150 μ m. As a precaution, the aiming beam was initially focused slightly posterior to the capsule towards the retina. If no visible damage occurred on the posterior capsule or if the laser-induced breakdown (LIB) seen as a spark appeared too posteriorly to the capsule, the aiming beam was cautiously moved backward nearer to the posterior capsule until visible damage on the capsule was seen. The CGPL lens (Haag Streit) was used in all procedures. To avoid IOL pitting, a centrally cruciate pattern starting from upside down was used²⁶⁻²⁹. The total number of pulses used to create the Nd:YAG posterior capsulotomy was recorded. High-risk patients (glaucoma, high myopia, higher total energy used) received 125 mg of acetazolamide two times on the treatment day. All patients received dexamethasone eyedrops (Maxidex®) 3 times per day for a week and were reexamined one week after the treatment by their personal ophthalmologists.

This study included all patients with biomicroscopically detectable PCO who were referred for Nd:YAG laser capsulotomy by their personal ophthalmologists. The patients were selected according to the reduction of visual acuity due to capsule opacity, complaints of glare or monocular diplopia. 53 eyes (44 patients) were included in the study (25 men and 19 women). The patients ranged in age from 59 to 89 years (average age 76.49). All procedures were performed with an energy level of 1.6 mJ. The average total energy used was 104.72 mJ, ranging from 27.2 mJ to 320 mJ. The average number of pulses used was 65.5, ranging from 17 to 200.

Nd:YAG laser capsulotomies can be successfully performed with an energy level of 1.6 mJ, but at the expense of higher total energy used. Based on the recommendations of some published articles, a lower single-pulse energy (but higher total energy) was used^{15, 30} in our study. The total amount of energy delivered to the treatment site can be decreased by using higher single-pulse energy, but this may potentially lead to a higher incidence of adverse effects.

ACKNOWLEDGMENT

This research was carried out in a collaboration with the EU regional **Competency Center for Biomedical Engineering (www.bmecenter.com)**, coordinated by Laser and Health Academy (www.laserandhealthacademy.com), and partially supported by the European Regional Development Fund and the Slovenian government.

REFERENCES

- Hollick EJ, Spalton DJ, Ursell PG, et al. The effect of polymethylmethacrylate, silicone, and polyacrylic intraocular lenses on posterior capsular opacification 3 years after cataract surgery. *Ophthalmology* 1999;106:49-54; discussion 54-45.
- Schaumberg DA, Dana MR, Christen WG, Glynn RJ. A systematic overview of the incidence of posterior capsule opacification. *Ophthalmology* 1998;105:1213-1221.
- Apple DJ, Peng Q, Visessook N, et al. Eradication of posterior capsule opacification: documentation of a marked decrease in Nd:YAG laser posterior capsulotomy rates noted in an analysis of 5416 pseudophakic human eyes obtained postmortem. *Ophthalmology* 2001;108:505-518.
- Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification. *Surv Ophthalmol* 1992;37:73-116.
- Billotte C, Berdeaux G. Adverse clinical consequences of neodymium:YAG laser treatment of posterior capsule opacification. *J Cataract Refract Surg* 2004;30:2064-2071.
- Ranta P, Tommila P, Immonen I, Summanen P, Kivela T. Retinal breaks before and after neodymium:YAG posterior capsulotomy. *J Cataract Refract Surg* 2000;26:1190-1197.
- Ranta P, Tommila P, Kivela T. Retinal breaks and detachment after neodymium: YAG laser posterior capsulotomy: five-year incidence in a prospective cohort. *J Cataract Refract Surg* 2004;30:58-66.
- Newland TJ, McDermott ML, Elliott D, et al. Experimental neodymium:YAG laser damage to acrylic, poly(methyl methacrylate), and silicone intraocular lens materials. *J Cataract Refract Surg* 1999;25:72-76.
- Aron-Rosa DS, Aron JJ, Cohn HC. Use of a pulsed picosecond Nd:YAG laser in 6,664 cases. *J Am Intraocul Implant Soc* 1984;10:35-39.
- Channell MM, Beckman H. Intraocular pressure changes after neodymium-YAG laser posterior capsulotomy. *Arch Ophthalmol* 1984;102:1024-1026.
- Ficker LA, Steele AD. Complications of Nd:YAG laser posterior capsulotomy. *Trans Ophthalmol Soc U K* 1985;104 (Pt 5):529-532.
- Geerling G, Roider J, Schmidt-Erfurt U, et al. Initial clinical experience with the picosecond Nd:YLF laser for intraocular therapeutic applications. *Br J Ophthalmol* 1998;82:504-509.
- Kraff MC, Sanders DR, Lieberman HL. Intraocular pressure and the corneal endothelium after neodymium-YAG laser posterior capsulotomy. Relative effects of aphakia and pseudophakia. *Arch Ophthalmol* 1985;103:511-514.
- Slomovic AR, Parrish RK, 2nd, Forster RK, Cubillas A. Neodymium:YAG laser posterior capsulotomy. Central corneal endothelial cell density. *Arch Ophthalmol* 1986;104:536-538.
- Auffarth GU, Nimsger C, Tetz MR, Volcker HE. [Analysis of energy levels for Nd:YAG laser capsulotomy in secondary cataract]. *Ophthalmologie* 2000;97:1-4.
- Bath PE, Romberger AB, Brown P. A comparison of Nd:YAG laser damage thresholds for PMMA and silicone intraocular lenses. *Invest Ophthalmol Vis Sci* 1986;27:795-798.
- Beale AB, Salmon J, Michau TM, Gilger BC. Effect of ophthalmic Nd:YAG laser energy on intraocular lenses after posterior capsulotomy in normal dog eyes. *Vet Ophthalmol* 2006;9:335-340.
- Capon MR, Docchio F, Leoni G, Trabucchi G, Brancato R. Comprehensive study of damage to intraocular lenses by single and multiple nanosecond neodymium:YAG laser pulses. *J Cataract Refract Surg* 1990;16:603-610.
- Dick B, Schwenn O, Pfeiffer N. [Extent of damage to different intraocular lenses by neodymium:YAG laser treatment--an experimental study]. *Klin Monbl Augenheilkd* 1997;211:263-271.
- Fallor MK, Hoft RH. Intraocular lens damage associated with posterior capsulotomy: a comparison of intraocular lens designs and four different Nd:YAG laser instruments. *J Am Intraocul Implant Soc* 1985;11:564-567.
- Newland TJ, Auffarth GU, Wesendahl TA, Apple DJ. Neodymium:YAG laser damage on silicone intraocular lenses. A comparison of lesions on explanted lenses and experimentally produced lesions. *J Cataract Refract Surg* 1994;20:527-533.
- Saffra N, Agarwal S, Enin J, Werner L, Mamalis N. In vitro analysis of Nd:YAG laser damage to hydrophilic intraocular lenses. *Ophthalmic Surg Lasers Imaging* 43:45-49.
- Trinavarat A, Atchaneeyasakul L, Udompunturak S. Neodymium:YAG laser damage threshold of foldable intraocular lenses. *J Cataract Refract Surg* 2001;27:775-780.
- Wilson SE, Brubaker RF. Neodymium: YAG laser damage threshold. A comparison of injection-molded and lathe-cut polymethylmethacrylate intraocular lenses. *Ophthalmology* 1987;94:7-11.
- Gomaa A, Liu C. Nd:YAG laser capsulotomy: a survey of UK practice and recommendations. *Eur J Ophthalmol* 21:385-390.
- Goble RR, O'Brart DP, Lohmann CP, Fitzke F, Marshall J. The role of light scatter in the degradation of visual performance before and after Nd:YAG capsulotomy. *Eye (Lond)* 1994;8 (Pt 5):530-534.
- Hu CY, Woung LC, Wang MC. Change in the area of laser posterior capsulotomy: 3 month follow-up. *J Cataract Refract Surg* 2001;27:537-542.
- Levy JH, Pisacano AM. Comparison of techniques and clinical results of YAG laser capsulotomy with two Q-switched units. *J Am Intraocul Implant Soc* 1985;11:131-133.
- Murrill CA, Stanfield DL, Van Brocklin MD. Capsulotomy. *Optom Clin* 1995;4:69-83.
- Bhargava R, Kumar P, Prakash A, Chaudhary KP. Estimation of mean Nd:YAG laser capsulotomy energy levels for membranous and fibrous posterior capsular opacification. *Nepal J Ophthalmol* 4:108-113.

The intent of this Laser and Health Academy publication is to facilitate an exchange of information on the views, research results, and clinical experiences within the medical laser community. The contents of this publication are the sole responsibility of the authors and may not in any circumstances be regarded as official product information by medical equipment manufacturers. When in doubt, please check with the manufacturers about whether a specific product or application has been approved or cleared to be marketed and sold in your country.